Ernesto Ayala1. 1. Blood and Marrow Transplant Program, Moffitt Cancer Center, Tampa, FL 33612, USA. Ernesto.Ayala@moffitt.org
Abstract
BACKGROUND: B-cell lymphoma comprises the majority of non-Hodgkin lymphomas worldwide. Hematopoietic cell transplantation (HCT) is used for patients with high-risk, relapsed, or refractory B-cell lymphoma. METHODS: The current medical literature and the results of recently published trials were reviewed to provide an update on the most common indications for HCT in B-cell lymphoma. RESULTS: Autologous HCT has evolving and new roles in the treatment of patients with high-risk diffuse large B-cell cell lymphoma, mantle cell lymphoma, and HIV-related lymphoma. Reduced-intensity conditioning has largely replaced older myeloablative conditioning regimens, making allogeneic transplantation safer for more patients with lymphoma. CONCLUSIONS: The indication and timing of HCT depend on the patient's histology, age, and response to previous therapies. HCT is an essential component in the armamentarium to treat B-cell lymphoma.
BACKGROUND:B-cell lymphoma comprises the majority of non-Hodgkin lymphomas worldwide. Hematopoietic cell transplantation (HCT) is used for patients with high-risk, relapsed, or refractory B-cell lymphoma. METHODS: The current medical literature and the results of recently published trials were reviewed to provide an update on the most common indications for HCT in B-cell lymphoma. RESULTS: Autologous HCT has evolving and new roles in the treatment of patients with high-risk diffuse large B-cell cell lymphoma, mantle cell lymphoma, and HIV-related lymphoma. Reduced-intensity conditioning has largely replaced older myeloablative conditioning regimens, making allogeneic transplantation safer for more patients with lymphoma. CONCLUSIONS: The indication and timing of HCT depend on the patient's histology, age, and response to previous therapies. HCT is an essential component in the armamentarium to treat B-cell lymphoma.
Authors: Basem M William; Tao Wang; Michael D Haagenson; Katharina Fleischhauer; Michael Verneris; Katharine C Hsu; Marcos J de Lima; Marcelo Fernandez-Viña; Stephen R Spellman; Stephanie J Lee; Brian T Hill Journal: Biol Blood Marrow Transplant Date: 2017-11-16 Impact factor: 5.742
Authors: Mira Romany Massoud; Paolo Fabrizio Caimi; Nicole Ferrari; Pingfu Fu; Richard Creger; Robert Fox; Joanne Carlson-Barko; Merle Kolk; Lauren Brister; Brenda Wimpfheimer Cooper; Stanton Gerson; Hillard Michael Lazarus; Marcos de Lima; Basem Magdy William Journal: Rev Bras Hematol Hemoter Date: 2016-08-18